Article info
Review
Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials
- Correspondence to A/Prof Kylie L Gorringe, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; kylie.gorringe{at}petermac.org
Citation
Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials
Publication history
- Received May 5, 2022
- Accepted July 12, 2022
- First published September 6, 2022.
Article Versions
- You are currently viewing a Previous version of this article (6 September 2022).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.